Rua Life Sciences PLC
Research Rua Life Sciences PLC (RUA) on Bullrun: market cap GBX 1.64B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRUA
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryMedical Devices
- CurrencyGBX
- Market capGBX 1.64B
- Financial periodFY2024
- RevenueGBP 2.19M
- Revenue growth0.6%
- Net income-GBP 1.44M
- Free cash flow-GBP 1.38M
- Gross margin81.1%
Valuation Snapshot
latest market cap is GBX 1.64B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2024 | GBP 2.19M | -GBP 1.44M | -GBP 1.38M | 81.1% | -0.04 | GBP 3.93M | GBP 389.00K | GBP 7.18M |
| FY2023 | GBP 2.18M | -GBP 2.00M | -GBP 1.60M | 82.2% | -0.09 | GBP 1.48M | GBP 475.00K | GBP 4.68M |
| FY2022 | GBP 1.63M | -GBP 2.07M | -GBP 3.26M | 83.6% | -0.09 | GBP 2.96M | GBP 344.00K | GBP 6.58M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | GBX 1.64B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 GBX.
About Rua Life Sciences PLC
RUA Life Sciences plc, together with its subsidiaries, develops medical devices in Europe, North America, the Middle East, the Asia Pacific, and Africa. It operates through four segments: Biomaterials, Contract Manufacture, Vascular, and Structural Heart. The company acts as the depository of intellectual property and licensing rights to various biostable and implantable polymers, including Elast-Eon and ECSil;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Rua Life Sciences PLC's market cap?
Rua Life Sciences PLC's market capitalization is GBX 1.64B.
What does Rua Life Sciences PLC do?
RUA Life Sciences plc, together with its subsidiaries, develops medical devices in Europe, North America, the Middle East, the Asia Pacific, and Africa. It operates through four segments: Biomaterials, Contract Manufacture, Vascular, and Structural Heart. The company acts as the depository of intellectual property and licensing rights to various biostable and implantable polymers, including Elast-Eon and ECSil; and provides sub-contract manufacturing, assembly, packing, and services of medical device, as well as implantable fabric.